Development of therapeutic RNA interference of human melanoma for the purpose of database design
Project/Area Number |
24791168
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Kyoto Prefectural University of Medicine |
Principal Investigator |
NAKAI Noriaki 京都府立医科大学, 医学(系)研究科(研究院), 講師 (80453108)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
Keywords | メラノーマ / 分子治療 / Mitf / ヒト / 遺伝子治療 / 悪性黒色腫 / 治療 / siRNA |
Outline of Final Research Achievements |
We synthesized 6 types of CRISPR/Cas9-Mitf corresponding to the Mitf sequence which is involved in melanin synthesis as well as differentiation of melanocyte and melanoma, and transfected them into human melanoma cell lines. CRISPR/Cas9-Mitf-4-mediated knockout of Mitf suppressed viability of HMV-II melanoma by 13% in comparison with control HMV-II melanoma. Low expression of Mitf mRNA in control amelanotic human melanoma SK-Mel 28 and in control melanotic human melanoma G361, and high expression of Mitf mRNA in control melanotic human melanoma HMV-II were confirmed. CRISPR/Cas9-mediated knockout of Mitf might suppress growth of certain types of human melanoma. While Mitf mRNA expression levels in human melanoma might not be associated with melanin production ability.
|
Report
(4 results)
Research Products
(40 results)